The pso Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the pso Hub cannot guarantee the accuracy of translated content. The pso and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Brought to you by Scientific Education Support

The PsOPsA Hub is supported by educational grants. All educational content is developed independently by SES in collaboration with our expert steering committee, with no input or influence from financial supporters. We would like to express our gratitude to the following companies for their support: • UCB: For website development, launch, and ongoing maintenance. • UCB: For educational content and news updates.

View all

Now you can support HCPs in making informed decisions for their patients

Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.

Find out more

Create an account and access these new features:

Bookmark content to read later

Select your specific areas of interest

View pso content recommended for you

LIMMitless trial: Long-term safety and efficacy of risankizumab in patients with moderate-to-severe plaque psoriasis

By Sheetal Burke

Feb 5, 2024

Learning objective: After reading this article, readers will be able to discuss the long-term safety and efficacy of risankizumab in patients with moderate-to-severe plaque psoriasis.

Test your knowledge! Take our quick quiz before and after you read this article to find out if you improved your knowledge. Results help us to improve content and continually provide open-access education.

Question 1 of 2

In the long-term analysis of the LIMMitless trial by Papp et al., what proportion of patients achieved an equal to or greater than 90% improvement in Psoriasis Area and Severity Index at Week 256?

Risankizumab, a monoclonal antibody that blocks the action of interleukin-23, was evaluated for the treatment of moderate-to-severe plaque psoriasis in the ongoing phase III LIMMitless trial (NCT03047395). There is limited data on the long-term safety and efficacy of risankizumab; in the IMMpulse trial, risankizumab demonstrated greater efficacy compared with apremilast in patients with plaque psoriasis.

Papp et al.¹ recently published the long-term safety and efficacy data from the LIMMitless trial in Journal of American Academy of Dermatology; here, the Psoriasis and Psoriatic Arthritis Hub is pleased to present a visual abstract summarizing the key findings.